Research Topics
| G B AppelSummaryAffiliation: Columbia University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Detecting and controlling diabetic nephropathy: What do we know?Gerald Appel
Presbyterian Hospital, 622 West 168th Street, Room 4124, New York, NY 10032
Cleve Clin J Med 80:209-17. 2013..The major ways to prevent or slow its progression are by reducing blood pressure, controlling blood sugar, and inhibiting the renin-angiotensin-aldosterone axis. New therapeutic agents are also being tried...- New diagnostic tests and new therapies for glomerular diseasesGerald B Appel
Glomerular Kidney Disease Center, Division of Nephrology, Columbia University Medical Center, and College of Physicians and Surgeons, Columbia University, New York, NY, USA
Blood Purif 35:81-5. 2013.... - New and future therapies for lupus nephritisGerald B Appel
Presbyterian Hospital, New York, NY 10032, USA
Cleve Clin J Med 79:134-40. 2012..The roles of rituximab (Rituxan) and new immunomodulatory agents are being explored. Creativity in treating lupus nephritis is needed; one regimen does not fit all... - The treatment of acute interstitial nephritis: More data at lastG B Appel
Columbia University College of Physicians and Surgeons, New York, New York, USA
Kidney Int 73:905-7. 2008..The study by González et al., although it has limitations, provides solid support for the early use of corticosteroids in the treatment of drug-related AIN... 
Use of mycophenolate mofetil in autoimmune and renal diseasesGerald B Appel
Department of Nephrology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Transplantation 80:S265-71. 2005..This article will review the published data and the experience of two major New York medical centers with the use of MMF in autoimmune and renal diseases...- Angiotensin II receptor antagonists: role in hypertension, cardiovascular disease, and renoprotectionGerald B Appel
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Prog Cardiovasc Dis 47:105-15. 2004 - Course and prognosis of human immunodeficiency virus-associated nephropathyL Carbone
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York
Am J Med 87:389-95. 1989..Patient survival is dependent upon the stage of HIV infection. These findings may prove useful in devising more effective strategies for the care of this growing patient population... - Fibrillary and immunotactoid glomerulonephritis: Distinct entities with different clinical and pathologic featuresJordan L Rosenstock
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Kidney Int 63:1450-61. 2003..Differentiation of FGN from the much more rare entity IT appears justified on immunopathologic, ultrastructural, and clinical grounds... - Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation. Report of 2 cases and review of the literatureJ Lin
Division of Nephrology, Department of Medicine, Columbia University, New York Presbyterian Hospital, New York, N Y, USA
Am J Nephrol 21:351-6. 2001..The close temporal association as well as evidence from murine models of GVHD support a pathogenetic association between GVHD and the development of MG... - Antiphospholipid antibody syndrome and renal diseaseR E Joseph
Department of Medicine, Division of Nephrology, Columbia Presbyterian Medical Center, New York, New York, USA
Curr Opin Nephrol Hypertens 10:175-81. 2001..The use of immunosuppressive agents has had no dramatic effect on antiphospholipid antibody titers and little clinical effect on thrombotic events... - Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfectionJ T Cheng
Department of Medicine at Harlem Hospital Center, New York, New York 10037, USA
J Am Soc Nephrol 10:1566-74. 1999..Although hypocomplementemia, cryoglobulinemia, and more prominent hypertension and microscopic hematuria may provide clues to the presence of HCV-GD, renal biopsy is essential to differentiate HCV-GD from HIV-associated nephropathy... - Heavy chain deposition disease: the disease spectrumN Kambham
Department of Pathology, Renal Pathology Laboratory, New York, NY, USA
Am J Kidney Dis 33:954-62. 1999..There is no effective treatment for this condition, and virtually all patients progress to chronic renal failure... 
Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantationBen Sprangers
Department of Medicine, Division of Nephrology, Columbia University, College of Physicians and Surgeons, New York, New York, USA
Clin J Am Soc Nephrol 5:790-7. 2010..It is known that iMN may recur after kidney transplantation, causing proteinuria, allograft dysfunction, and allograft loss. Limited data regarding the frequency and treatment of recurrent iMN are available...- Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritisSamih H Nasr
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, New York 10032, USA
Kidney Int 65:85-96. 2004..Proper recognition of this entity requires confirmation of monoclonality by staining for the gamma heavy chain subclasses... - An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseasesAlice S Appel
Columbia University Medical Center, New York, NY 10032, USA
Nat Clin Pract Nephrol 5:132-42. 2009..Only through large, collaborative, controlled trials will the true role of MMF be defined for each glomerular disease... - Renal monoclonal immunoglobulin deposition disease: the disease spectrumJ Lin
Division of Nephrology, Department of Medicine, Columbia University, New York-Presbyterian Hospital, 630 W. 168th Street, New York, NY 10032, USA
J Am Soc Nephrol 12:1482-92. 2001..0 mg/dl, emphasizing the importance of early detection. On multivariate analysis, initial creatinine was the only predictor of renal and patient survival in pure MIDD, underscoring the prognostic significance of the renal involvement... - A new apolipoprotein E mutation, apoE Las Vegas, in a European-American with lipoprotein glomerulopathyAndrew S Bomback
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Nephrol Dial Transplant 25:3442-6. 2010..Whereas prior European-American patients with lipoprotein glomerulopathy were found to have the previously reported apoE Kyoto genotype, the patient presented here was found to have a novel mutation that we have named apoE Las Vegas... - Proliferative glomerulonephritis with monoclonal IgG depositsSamih H Nasr
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
J Am Soc Nephrol 20:2055-64. 2009..We conclude that proliferative glomerulonephritis with monoclonal IgG deposits does not seem to be a precursor of myeloma in the vast majority of patients... - Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritisJai Radhakrishnan
Department of Medicine, Columbia University Medical Center, 622 W 168th St, New York, NY 10032, USA
Kidney Int 77:152-60. 2010..Hence we found that the response to MMF as induction treatment of patients with class V LN appears to be no different from that to IVC... - Dense deposit disease: clinicopathologic study of 32 pediatric and adult patientsSamih H Nasr
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Clin J Am Soc Nephrol 4:22-32. 2009..Dense deposit disease (DDD) is a rare disorder that most commonly affects children. This study reports the largest North American series addressing clinicopathologic and outcome differences in children and adults... - Renal transplantation in familial dysautonomia: report of two cases and review of the literatureYelena Rekhtman
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Clin J Am Soc Nephrol 5:1676-80. 2010..Transplant was performed after 3 months on intermittent hemodialysis (HD) in the first case and after 1 month on twice-weekly continuous veno-venous hemodialysis (CVVHD) in the second case... - Mycophenolate mofetil for the treatment of interstitial nephritisDean C Preddie
Department of Medicine Division of Nephrology, Columbia University College of Physicians and Surgeons, 622 West 168th Street, PH4 124, New York, NY 10032, USA
Clin J Am Soc Nephrol 1:718-22. 2006..4 mo. MMF was well tolerated by all patients. It is concluded that MMF is a useful therapeutic option for steroid-resistant AIN and may be considered as potential first-line therapy in select populations... - Pauci-immune crescentic glomerulonephritis superimposed on diabetic glomerulosclerosisSamih H Nasr
Department of Pathology, Columbia University, College of Physicians and Surgeons, 630 West 168th Street, VC14 224, New York, NY 10032, USA
Clin J Am Soc Nephrol 3:1282-8. 2008..Pauci-immune necrotizing and crescentic glomerulonephritis (PNCGN) superimposed on diabetic glomerulosclerosis (DGS) is a rare occurrence. Only limited data on this dual glomerulopathy are available... - Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronateG S Markowitz
Department of Pathology, Columbia College of Physicians and Surgeons, New York, New York 10032, USA
J Am Soc Nephrol 12:1164-72. 2001..These data provide the first association of collapsing FSGS with toxicity to a therapeutic agent... - COX-2 inhibitors and the kidneyG B Appel
Columbia Presbyterian Medical Center, New York, USA
Clin Exp Rheumatol 19:S37-40. 2001..Judicious use of COX-2 inhibitors in high-risk patients (such as those with chronic renal insufficiency, diabetes or congestive heart failure) will lead to a decreased incidence of adverse renal events... - Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritisGerald B Appel
Department of Nephrology, Columbia University, New York, New York, USA
J Am Soc Nephrol 20:1103-12. 2009..Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis... - Improved outcomes in nephrotic syndromeGerald B Appel
Columbia University College of Physicians and Surgeons, New York, NY, USA
Cleve Clin J Med 73:161-7. 2006..Depending on the condition, additional treatment may include corticosteroids, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), cyclosporine, cytotoxic agents, or mycophenolate... - Multiple myeloma, nephrotic syndrome and crystalloid inclusions in podocytesS H Nasr
Department of Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
Kidney Int 69:616-20. 2006 - Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipientsA Matalon
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, 10032, USA
Clin Nephrol 56:271-8. 2001..Predictors of response to PP include early initiation of treatment after recurrence and possibly an early recurrence of disease... - Membranous glomerulopathy and acute interstitial nephritis following treatment with celecoxibG S Markowitz
Department of Pathology, Columbia University, College of Physicians and Surgeons, New York, NY 10032, USA
Clin Nephrol 59:137-42. 2003..These cases enlarge the spectrum of potential renal toxicities of the COX-2-specific non-steroidal anti-inflammatory drugs... - Rituximab treatment of dysproteinemias affecting the kidney: a review of three casesPremila Bhat
Department of Medicine Nephrology, Columbia University Medical Center, New York, NY, USA
Am J Kidney Dis 50:641-4. 2007..Additional clinical studies should be planned... - Hyperlipidemia and thrombotic complications in patients with membranous nephropathyThomas L Nickolas
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Semin Nephrol 23:406-11. 2003..Prospective trials in the future will provide definitive information on how to best treat these abnormalities... - Analysis of metabolic parameters as predictors of risk in the RENAAL studyGerald B Appel
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
Diabetes Care 26:1402-7. 2003..CONCLUSIONS: Overall, losartan was well tolerated by patients with type 2 diabetes and nephropathy and was associated with a favorable effect on the metabolic profile of this population... - Glomerular disease: why is there a dearth of high quality clinical trials?David E Leaf
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA
Kidney Int 78:337-42. 2010.... - Recurrent glomerulonephritis after renal transplantation: an unsolved problemWilliam A Golgert
Division of Nephrology, Medical College of Wisconsin, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
Clin J Am Soc Nephrol 3:800-7. 2008..This study analyzed prevalence and outcome of recurrent glomerulonephritis from various registries... - Racial and socioeconomic factors in glomerular diseaseD Halevy
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA
Semin Nephrol 21:403-10. 2001..Whether racial and socioeconomic data should be used in treating individual patients, and how, remains an area of controversy... - The IgA nephropathy treatment dilemmaG B Appel
Department of Medicine, Division of Nephrology, Columbia Presbyterian, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA
Kidney Int 69:1939-44. 2006.... - Minimal change disease in systemic lupus erythematosusG K Dube
Department of Pathology, Columbia University, New York Presbyterian Hospital, NY, USA
Clin Nephrol 57:120-6. 2002..Proper recognition of this entity requires careful integration of the renal biopsy immunofluorescence and electron microscopic findings... - Membranoproliferative glomerulonephritis type II (dense deposit disease): an updateGerald B Appel
Columbia University, Department of Nephrology, New York, New York, USA
J Am Soc Nephrol 16:1392-403. 2005..The development of molecular diagnostic tools and new therapies directed at controlling the AP of the complement cascade either locally in the kidney or at the systemic level may lead to effective treatments for MPGN II... - Collapsing glomerulopathyJoshua A Schwimmer
Division of Nephrology, Department of Medicine, Columbia College of Physicians and Surgeons, New York, NY, USA
Semin Nephrol 23:209-18. 2003..The role of other immunosuppressive agents such as mycophenolate mofetil in the treatment of collapsing FSGS remains to be defined. Prospective clinical trials are needed to define optimal therapy of this aggressive form of FSGS... - Updates on the treatment of lupus nephritisAndrew S Bomback
Department of Medicine, Division of Nephrology, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
J Am Soc Nephrol 21:2028-35. 2010..Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials... - NPHS2 variation in focal and segmental glomerulosclerosisStephen J Tonna
Renal Division, Department of Medicine, Brigham and Women s Hospital, Boston, Massachusetts, USA
BMC Nephrol 9:13. 2008..Homozygous or compound heterozygous mutations in the podocin gene NPHS2 are found in 10-30% of pediatric cases of steroid resistant nephrosis and/or FSGS... - Fludarabine treatment of cryoglobulinemic glomerulonephritisJordan L Rosenstock
Department of Medicine, College of Physicians and Surgeons of Columbia University, New York, NY, USA
Am J Kidney Dis 40:644-8. 2002..Transient blindness and neutropenia were seen in another patient. These results suggest that fludarabine may be a useful treatment in cryoglobulinemia with glomerulonephritis, although its use may be accompanied by side effects... - Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathyW Kline Bolton
Department of Medicine, University of Virginia Health System, Charlottesville, Va 2908 0133, USA
Am J Nephrol 24:32-40. 2004..This study was undertaken to determine if pimagedine ameliorates nephropathy in type 1 (insulin-dependent) diabetes mellitus... - Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicityR Graham Barr
Columbia Presbyterian Medical Center, 622 West 168th Street, New York, NY 10032, USA
Nephrol Dial Transplant 18:2039-46. 2003..Given these findings, some of the poorer prognosis of African-American patients with PLN may result from socio-economic rather than biological or genetic factors... - Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritisEllen M Ginzler
Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
N Engl J Med 353:2219-28. 2005..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable... - NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated alleleHiroyasu Tsukaguchi
Department of Laboratory Medicine, University of Tokushima, Tokushima, Japan
J Clin Invest 110:1659-66. 2002..Identification of R229Q mutations may be of clinical importance, as NPHS2-associated disease appears to define a subgroup of FSGS patients unresponsive to corticosteroids... - The classification of glomerulonephritis in systemic lupus erythematosus revisitedJan J Weening
Academic Medical Center, University of Amsterdam, The Netherlands
Kidney Int 65:521-30. 2004..We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification... - The classification of glomerulonephritis in systemic lupus erythematosus revisitedJan J Weening
Academic Medical Center University of Amsterdam, Amsterdam, The Netherlands
J Am Soc Nephrol 15:241-50. 2004..We hope that this revision, which evolved under the auspices of the International Society of Nephrology and the Renal Pathology Society, will contribute to further advancement of the WHO classification... - To treat or not to treat IgA nephropathy? That is the question!Gerald B Appel
Clin J Am Soc Nephrol 1:347-8. 2006 - Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trialMario H Cardiel
Hospital General Dr Miguel Silva, Morelia, Michoacan, Mexico
Arthritis Rheum 58:2470-80. 2008.... - Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL studyAndrew M Tershakovec
Merck Research Laboratories, Merck and Co, Inc, Upper Gwynedd, Pennsylvania, USA
Diabetes Care 31:445-7. 2008..LDL cholesterol lowering was associated with a lower risk of ESRD; however, this seemed to be largely an association with the reduction in albuminuria...